Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXAGEN INC.XGN · Entity 935 | Director | June 09, 2026 | August 19, 2026 |
| Fulgent Genetics, Inc.FLGT · Entity 2545 | CFO and Treasurer | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXAGEN INC.
Report date June 09, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2036-06-08 | Direct | 46,500 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 37,500 · Balance 46,500 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Fulgent Genetics, Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 356,543 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 2,087 · Balance 356,543 F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 23:48 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,087 | $19.59 | $40,884.33 |
DisclosureSEC source: 0001253820-26-000011 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,543 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 22:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,168 | $19.81 | $23,138.08 |
DisclosureSEC source: 0001253820-26-000009 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,630 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| July 26, 2026 Filed Jul 28, 2026 20:32 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,747 | $19.67 | $54,033.49 |
DisclosureSEC source: 0001193125-26-321087 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,798 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| June 09, 2026 Filed Aug 19, 2026 22:57 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 37,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001274737-26-000054 · wk-form4_1787180231.xml · derivative · entry 1 Kim Paul · CIK 0001253820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,500 Underlying: Common Stock · 37,500 shares Expires 2036-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:29 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,087 | $18.09 | $37,753.83 |
DisclosureSEC source: 0001253820-26-000005 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,545 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. Read SEC document |
| May 26, 2026 Filed May 28, 2026 21:19 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,168 | $17.67 | $20,638.56 |
DisclosureSEC source: 0001253820-26-000003 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,632 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| April 26, 2026 Filed Apr 28, 2026 20:51 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,747 | $16.31 | $44,803.57 |
DisclosureSEC source: 0001193125-26-187445 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,800 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 01:01 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 8,347 | $15.33 | $127,959.51 |
DisclosureSEC source: 0001253820-26-000001 · ownership.xml · nonDerivative · entry 3 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,547 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 01:01 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,133 | $15.33 | $17,368.89 |
DisclosureSEC source: 0001253820-26-000001 · ownership.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,894 F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, , which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:01 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,168 | $24.76 | $28,919.68 |
DisclosureSEC source: 0001253820-26-000001 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,027 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 31,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072641 · ownership.xml · nonDerivative · entry 8 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,195 F8 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2026, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 15,095 | $23.09 | $348,543.55 |
DisclosureSEC source: 0001193125-26-072641 · ownership.xml · nonDerivative · entry 7 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,013 F7 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 25, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 8,456 | $23.09 | $195,249.04 |
DisclosureSEC source: 0001193125-26-072641 · ownership.xml · nonDerivative · entry 6 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,108 F6 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,241 | $23.09 | $74,834.69 |
DisclosureSEC source: 0001193125-26-072641 · ownership.xml · nonDerivative · entry 5 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371,564 F5 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 26,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072641 · ownership.xml · nonDerivative · entry 4 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,805 F4 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 25, 2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 14,926 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072641 · ownership.xml · nonDerivative · entry 3 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,132 F3 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 5,721 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-072641 · ownership.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,206 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 01:18 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 661 | $23.01 | $15,209.61 |
DisclosureSEC source: 0001193125-26-072641 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 327,485 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 22:01 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,004 | $27.53 | $82,700.12 |
DisclosureSEC source: 0001193125-26-027397 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,146 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,131 | $28.52 | $32,256.12 |
DisclosureSEC source: 0001193125-25-306924 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,150 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| November 26, 2025 Filed Dec 2, 2025 00:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,166 | $30.15 | $35,154.90 |
DisclosureSEC source: 0001193125-25-304201 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,281 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| November 23, 2025 Filed Nov 25, 2025 21:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 671 | $30.00 | $20,130.00 |
DisclosureSEC source: 0001193125-25-297326 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,447 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| October 26, 2025 Filed Oct 28, 2025 21:20 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,743 | $23.74 | $65,118.82 |
DisclosureSEC source: 0001193125-25-253872 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 334,118 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 21:31 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,131 | $22.17 | $25,074.27 |
DisclosureSEC source: 0001253820-25-000008 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,861 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 22:55 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,166 | $21.47 | $25,034.02 |
DisclosureSEC source: 0001253820-25-000006 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,992 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| August 23, 2025 Filed Aug 26, 2025 23:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 670 | $21.77 | $14,585.90 |
DisclosureSEC source: 0001253820-25-000004 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,158 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| July 26, 2025 Filed Jul 29, 2025 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,743 | $18.37 | $50,388.91 |
DisclosureSEC source: 0000950170-25-099793 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 339,828 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:32 UTC Amendment | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001274737-25-000051 · wk-form4a_1749774721.xml · derivative · entry 1 Kim Paul · CIK 0001253820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2035-06-09 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. F2 · balance_after: On June 12, 2025, the reporting person filed a Form 4 which inadvertently reported that, following his grant of 9,000 stock options, he beneficially owned 18,000 stock options. In fact, as reported in this amendment, the reporting person beneficially owned 9,000 stock options. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 21:57 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $7.36 | $0.00 |
DisclosureSEC source: 0001274737-25-000046 · wk-form4_1749765431.xml · derivative · entry 1 Kim Paul · CIK 0001253820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 9,000 shares Expires 2035-06-09 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:47 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,131 | $20.72 | $23,434.32 |
DisclosureSEC source: 0000950170-25-081053 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,571 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| May 26, 2025 Filed May 28, 2025 20:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,166 | $20.31 | $23,681.46 |
DisclosureSEC source: 0000950170-25-078348 · ownership.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,702 F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| May 23, 2025 Filed May 28, 2025 20:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 671 | $20.31 | $13,628.01 |
DisclosureSEC source: 0000950170-25-078348 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,868 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| April 26, 2025 Filed Apr 29, 2025 20:54 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,743 | $18.88 | $51,787.84 |
DisclosureSEC source: 0000950170-25-060280 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,539 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 05, 2025 Filed Mar 5, 2025 23:47 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | PurchaseCommon Stock | 100,000 | $15.96 | $1,596,470.00 |
DisclosureSEC source: 0000950170-25-033994 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,282 F1 · price: The shares were purchased in multiple transactions ranging from $15.48 to $16.60, inclusive. The reported price is the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 01:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,556 | $15.45 | $24,040.20 |
DisclosureSEC source: 0000950170-25-032775 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,282 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 02:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 4,662 | $16.24 | $75,710.88 |
DisclosureSEC source: 0000950170-25-029436 · ownership.xml · nonDerivative · entry 8 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,838 F8 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 44,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029436 · ownership.xml · nonDerivative · entry 7 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,500 F7 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after March 1, 2025, and 1/12th of such shares vesting at the end of every three-month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 8,228 | $16.29 | $134,034.12 |
DisclosureSEC source: 0000950170-25-029436 · ownership.xml · nonDerivative · entry 6 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,301 F6 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 26, 2024. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,024 | $16.29 | $49,260.96 |
DisclosureSEC source: 0000950170-25-029436 · ownership.xml · nonDerivative · entry 5 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,529 F5 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,914 | $16.29 | $31,179.06 |
DisclosureSEC source: 0000950170-25-029436 · ownership.xml · nonDerivative · entry 4 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,553 F4 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 13,949 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029436 · ownership.xml · nonDerivative · entry 3 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,467 F3 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 26, 2024. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 5,346 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029436 · ownership.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,518 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 25, 2025 Filed Feb 28, 2025 02:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 3,384 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-029436 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,172 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 22:25 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 733 | $16.46 | $12,065.18 |
DisclosureSEC source: 0000950170-25-026883 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,788 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| January 26, 2025 Filed Jan 28, 2025 21:29 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,000 | $17.21 | $51,630.00 |
DisclosureSEC source: 0000950170-25-009842 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,521 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| December 01, 2024 Filed Dec 4, 2024 21:41 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,553 | $18.30 | $28,419.90 |
DisclosureSEC source: 0000950170-24-133315 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,521 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| November 25, 2024 Filed Nov 27, 2024 22:00 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 669 | $17.87 | $11,955.03 |
DisclosureSEC source: 0000950170-24-131592 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,074 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| October 26, 2024 Filed Oct 29, 2024 20:30 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,738 | $19.42 | $53,171.96 |
DisclosureSEC source: 0000950170-24-118287 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,743 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,674 | $21.96 | $36,762.71 |
DisclosureSEC source: 0000950170-24-104024 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,481 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $21.815 to $22.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 27, 2024 Filed Aug 29, 2024 22:33 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 733 | $22.83 | $16,736.59 |
DisclosureSEC source: 0000950170-24-101986 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,155 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. F2 · price: The shares were sold in multiple transactions at prices ranging from $22.72 to $22.915, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.